BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 29330305)

  • 1. Restricted processing of CD16a/Fc γ receptor IIIa
    Patel KR; Roberts JT; Subedi GP; Barb AW
    J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD16a with oligomannose-type
    Subedi GP; Barb AW
    J Biol Chem; 2018 Oct; 293(43):16842-16850. PubMed ID: 30213862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Human Natural Killer Cells Retain Proinflammatory IgG1 at the Cell Surface and Express CD16a Glycoforms with Donor-dependent Variability.
    Patel KR; Nott JD; Barb AW
    Mol Cell Proteomics; 2019 Nov; 18(11):2178-2190. PubMed ID: 31467031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fc γ receptor IIIa/CD16a processing correlates with the expression of glycan-related genes in human natural killer cells.
    Patel KR; Rodriguez Benavente MC; Lorenz WW; Mace EM; Barb AW
    J Biol Chem; 2021; 296():100183. PubMed ID: 33310702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single amino acid distorts the Fc γ receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a.
    Roberts JT; Barb AW
    J Biol Chem; 2018 Dec; 293(51):19899-19908. PubMed ID: 30361439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-specific N-glycan Analysis of Antibody-binding Fc γ Receptors from Primary Human Monocytes.
    Roberts JT; Patel KR; Barb AW
    Mol Cell Proteomics; 2020 Feb; 19(2):362-374. PubMed ID: 31888963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody Fucosylation Lowers the FcγRIIIa/CD16a Affinity by Limiting the Conformations Sampled by the N162-Glycan.
    Falconer DJ; Subedi GP; Marcella AM; Barb AW
    ACS Chem Biol; 2018 Aug; 13(8):2179-2189. PubMed ID: 30016589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody receptors steal the sweet spotlight.
    Oliva KD; Cavanaugh JM; Cobb BA
    J Biol Chem; 2018 Mar; 293(10):3490-3491. PubMed ID: 29523693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allotype-specific processing of the CD16a N45-glycan from primary human natural killer cells and monocytes.
    Patel KR; Roberts JT; Barb AW
    Glycobiology; 2020 Jul; 30(7):427-432. PubMed ID: 31967297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
    Rodriguez Benavente MC; Hughes HB; Kremer PG; Subedi GP; Barb AW
    Immunology; 2023 Oct; 170(2):202-213. PubMed ID: 37218360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of N-Glycan Composition on Structure and Dynamics of IgG1 Fc and Their Implications for Antibody Engineering.
    Lee HS; Im W
    Sci Rep; 2017 Oct; 7(1):12659. PubMed ID: 28978918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface.
    Kremer PG; Barb AW
    J Biol Chem; 2022 Sep; 298(9):102329. PubMed ID: 35921896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry.
    Woodall DW; Dillon TM; Kalenian K; Padaki R; Kuhns S; Semin DJ; Bondarenko PV
    MAbs; 2022; 14(1):2004982. PubMed ID: 34978527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
    Front Immunol; 2018; 9():2873. PubMed ID: 30574146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor.
    Subedi GP; Barb AW
    MAbs; 2016; 8(8):1512-1524. PubMed ID: 27492264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors.
    Blundell PA; Le NPL; Allen J; Watanabe Y; Pleass RJ
    J Biol Chem; 2017 Aug; 292(31):12994-13007. PubMed ID: 28620050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbohydrate-Polypeptide Contacts in the Antibody Receptor CD16A Identified through Solution NMR Spectroscopy.
    Subedi GP; Falconer DJ; Barb AW
    Biochemistry; 2017 Jun; 56(25):3174-3177. PubMed ID: 28613884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
    Hodoniczky J; Zheng YZ; James DC
    Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Fc Gamma Receptor Glycoforms That Produce Differential Binding Kinetics for Rituximab.
    Hayes JM; Frostell A; Karlsson R; Müller S; Martín SM; Pauers M; Reuss F; Cosgrave EF; Anneren C; Davey GP; Rudd PM
    Mol Cell Proteomics; 2017 Oct; 16(10):1770-1788. PubMed ID: 28576848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.